Mamardashvili Giorgi, Botchorishvili Nazibrola, Kobaidze Gucha, Janelidze Marina
Neurology, Tbilisi State Medical University, Tbilisi, GEO.
Neurology, Simon Khechinashvili University Hospital, Tbilisi, GEO.
Cureus. 2025 May 7;17(5):e83652. doi: 10.7759/cureus.83652. eCollection 2025 May.
Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system in young adults. Disease-modifying therapies (DMTs) for MS target different aspects of the immune system and have various safety profiles. Fingolimod is a DMT introduced for the treatment of MS. Cutaneous adverse events have been well described in patients treated with fingolimod. We present a clinical case of a patient with relapsing-remitting multiple sclerosis (RRMS) who developed multiple skin lesions after four months of treatment with fingolimod. Diagnosis of seborrheic keratosis, nevi, and papilloma was made clinically based on characteristic lesion morphology. Histologic confirmation was not performed, and human papillomavirus (HPV) DNA testing was positive. Rapid progression of cutaneous lesions prompted the switch to a different DMT, after which the lesions resolved completely within two months.
多发性硬化症（MS）是年轻成年人中最常见的中枢神经系统脱髓鞘疾病。用于MS的疾病修正疗法（DMTs）针对免疫系统的不同方面，且具有不同的安全性。芬戈莫德是一种用于治疗MS的DMT。使用芬戈莫德治疗的患者中，皮肤不良事件已有详尽描述。我们报告一例复发缓解型多发性硬化症（RRMS）患者的临床病例，该患者在使用芬戈莫德治疗四个月后出现多处皮肤病变。根据特征性病变形态，临床诊断为脂溢性角化病、痣和乳头状瘤。未进行组织学确诊，人乳头瘤病毒（HPV）DNA检测呈阳性。皮肤病变的快速进展促使换用另一种DMT，此后病变在两个月内完全消退。
